Synlogic To Webcast Presentation At The LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

Published: Sep 21, 2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Synlogic (Nasdaq: SYBX) announced today that JC Gutiérrez-Ramos, Synlogic’s president and chief executive officer, will present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology at 4:00 p.m. ET on Wednesday, September 27, 2017, in New York City.

A live webcast of the presentation can be accessed under “Event Calendar” in the Investors & Media section of the Company’s website. An archived webcast recording will be available on the Synlogic website for approximately 30 days after the event.

About Synlogic:

Synlogic is pioneering the development of a novel class of living treatments, Synthetic BioticTM medicines, based on its proprietary drug development platform. Synlogic’s initial pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of more common diseases, including liver disease, inflammatory and immune disorders, and cancer. Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit www.synlogictx.com.

MEDIA CONTACT:
Synlogic
Courtney Heath, 617-872-2462
courtney@scientpr.com
or
INVESTOR CONTACT:
Synlogic
Elizabeth Wolffe, Ph.D., 617-207-5509
liz@synlogictx.com

Back to news